Cargando…
Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo
The majority of human melanomas bears BRAF mutations and thus is treated with inhibitors of BRAF, such as vemurafenib. While patients with BRAF mutations often demonstrate an initial dramatic response to vemurafenib, relapse is extremely common. Thus, novel agents are needed for the treatment of the...
Autores principales: | Bonner, Michael Y., Karlsson, Isabella, Rodolfo, Monica, Arnold, Rebecca S., Vergani, Elisabetta, Arbiser, Jack L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914326/ https://www.ncbi.nlm.nih.gov/pubmed/26871475 http://dx.doi.org/10.18632/oncotarget.7289 |
Ejemplares similares
-
Antineoplastic Effects of Honokiol on Melanoma
por: Guillermo-Lagae, Ruth, et al.
Publicado: (2017) -
Honokiol is a FOXM1 antagonist
por: Halasi, Marianna, et al.
Publicado: (2018) -
Pro-Apoptotic Activity of New Honokiol/Triphenylmethane Analogues in B-Cell Lymphoid Malignancies
por: Mędra, Aleksandra, et al.
Publicado: (2016) -
Honokiol blocks and reverses cardiac hypertrophy in mice by
activating mitochondrial SIRT3
por: Pillai, Vinodkumar B., et al.
Publicado: (2015) -
Dichloroacetate (DCA) and Cancer: An Overview towards Clinical Applications
por: Tataranni, Tiziana, et al.
Publicado: (2019)